Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel

Molecular Pharmacology

Volumn 72, Issue 1, 2007, Pages 197-207

  Pedemonte, Nicoletta ^a,b   Boido, Davide ^c   Moran, Oscar ^c   Giampieri, Michele ^d   Mazzei, Mauro ^d   Ravazzolo, Roberto ^a   Galietta, Luis J V ^a,b  

^a G GASLINI INSTITUTE   (Italy)

^b CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE; CHLORIDE CHANNEL; FELODIPINE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CELLS, CULTURED; CHLORIDE CHANNELS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIHYDROPYRIDINES; RATS; RATS, INBRED F344; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34347242438     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.034702     Document Type: Article

References (30)

1. Bobadilla J, Macek M, Fine JP, and Farrell PM (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 19:575-606.
2. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, and Lazdunski M (1991) Altered chloride ion channel kinetics associated with the F508 cystic fibrosis mutation. Nature 354:526-528.
3. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, and Welsh MJ (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358:761-764.
4. Freedman SB, Miller RJ (1984) Calcium channel activation: a different type of drug action. Proc Natl Acad Sci U S A 81:5580-5583.
5. Galietta LJV, Haggie PM, and Verkman AS (2001a) Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett 499:220-224.
6. Galietta LJV, Jayaraman S, and Verkman AS (2001b) Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol 281:C1734-C1742.
7. Hamosh A, King TM, Rosenstein BJ, Corey M, Levison H, Durie P, Tsui LC, McIntosh I, Keston M, Brock DJH, et al. (1992) Cystic fibrosis patients bearing the common missense mutation Gly to Asp at codon 551 and the ΔF508 mutation are clinically indistinguishable from ΔF508 homozygotes, except for a decreased risk of meconium ileus. Am J Hum Genet 51:245-250.
8. Harrold MW (2002) Angiotensin converting enzyme inhibitors, antagonists and calcium blockers, in Foye's Principles of Medicinal Chemistry (Williams DA and Lemke TL eds), 5th ed, pp 551-556, Lippincott Williams & Wilkins, Philadelphia.
9. Haws CM, Nepomuceno IB, Krouse ME, Wakelee H, Law T, Xia Y, Nguyen H, and Wine JJ (1996) ΔF508-CFTR channels: kinetics, activation by forskolin and potentiation by xanthines. Am J Physiol 270:C1544-C1555.
10. Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, and Schultz G (1991) L-type calcium channels, potassium channels, and novel nonspecific cation channels in a clonal muscle cell line derived from embryonic rat ventricle. Circ Res 69:1476-1486.
11. Hwang TC, Wang F, Yang IC, and Reenstra WW. (1997) Genistein potentiates wild-type and ΔF508-CFTR channel activity. Am J Physiol Cell Physiol 273:C988-C998.
12. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, and Higgins CF (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346:362-365.
13. Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, and Fischer H (1999) Defective function of the cystic fibrosis-causing mutation missense mutation G551D is recovered by genistein. Am J Physiol Cell Physiol 277:C833-C839.
14. Kopito RR (1999) Biosynthesis and degradation of CFTR. Physiol Rev 79:S167-S173.
15. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, and Verkman AS (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera-toxin induced intestinal fluid secretion. J Clin Invest 110:1651-1658.
16. Menard C, Pupier S, Mornet D, Kitzmann M, Nargeot J, Lory P (1999) Modulation of L-type calcium channel expression during retinoic acid-induced differentiation of H9C2 cardiac cells. J Biol Chem 274:29063- 29070.
17. Moran O, Galietta LJ, Zegarra-Moran O (2005) Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 62:446-460.
18. Moran O and Zegarra-Moran O (2005) A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein. FEBS Lett 579:3979-3983.
19. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, Robins LI, Dicus CW, Willenbring D, Nantz MH, et al. (2005a) Phenylglycine and sulfonamide correctors of defective ΔF508- and G551D-CFTR chloride channel gating. Mol Pharmacol 67:1797-1807.
20. Pedemonte N, Diena T, Caci E, Nieddu E, Mazzei M, Ravazzolo R, Zegarra-Moran O, Galietta LJ (2005b) Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol 68:1736-1746.
21. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJV, Verkman AS (2005c) Small molecule correctors of defective DF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115:2564-2571.
22. Pilewski JM and Frizzell RA. (1999) Role of CFTR in airway disease. Physiol Rev 79:S215-S255.
23. Sheppard DN and Welsh MJ. (1999) Structure and function of the CFTR chloride channel. Physiol Rev 79:S23-S45.
24. 2+? Naunyn Schmiedebergs Arch Pharmacol 328:464-466.
25. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, et al. (2006) Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290:L1117-L1130.
26. Wei XY, Luchowski EM, Rutledge A, Su CM, Triggle DJ (1986) Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activator-antagonist pairs in smooth muscle. J Pharmacol Exp Ther 239:144-153.
27. Welsh MJ and Smith AE (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251-1254.
28. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, et al. (2003) Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating. J Biol Chem 278:35079-35085.
29. Zegarra-Moran O, Monteverde M, Galietta LJ, and Moran O (2007) Functional analysis of mutations in the putative binding site for CFTR potentiators: Interaction between activation and inhibition. J Biol Chem 282:9098-9104.
30. Zegarra-Moran O, Romio L, Folli C, Caci E, Becq F, Vierfond JM, Mettey Y, Cabrini G, Fanen P, and Galietta LJV (2002) Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br J Pharmacol 137:504-512.